New combo therapy aims to extend survival in aggressive liver cancer

NCT ID NCT06823375

First seen Mar 17, 2026 · Last updated May 14, 2026 · Updated 7 times

Summary

This study tests whether adding targeted radiation (SBRT) to standard immunotherapy (atezolizumab plus bevacizumab) can improve survival in people with advanced liver cancer that has spread into the main portal vein. About 40 adults with this aggressive condition will receive the combination treatment. The goal is to see if the approach can extend life beyond the current average of about 7-8 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Clinical Oncology, Prince of Wales Hospital

    RECRUITING

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Clinical Oncology, Tuen Mun Hospital

    RECRUITING

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.